The important role of caspases in programmed neuronal death has been demonstrated in a variety of CNS disorders, including stroke. Caspase-3 is a major executioner caspase and has been identified as a key mediator of neuronal death in the acute stage of stroke. Acute inhibition of caspase-3 provides robust protection of neurons against ischemic and traumatic cell death. However, caspase-3 activation is also involved in a variety of biological processes that do not lead to cell death. Caspase-3 serves as a key endogenous component that negatively regulates neurogenesis after stroke. Caspase-3 inhibition may be a potential way to expand the brain's neurogenic capacity to repair damaged tissues after stroke.
Fig. 1. Increased expression of caspase-3 in the subventricular zone and the dentate gyrus during the period of stroke recovery. (Fan et al., 2014)
Based on the in vitro model of ischemic stroke through the oxygen-glucose deprivation (OGD) method, Ace Therapeutics offers highly sensitive and reliable in vitro caspase-3 activity assay services designed for stroke drug discovery. The assay quantifies apoptosis levels in living neuronal cells and enables the evaluation of potential stroke drugs.
Colorimetric Determination of Caspase-3 Activity
Ace Therapeutics's caspase-3 colorimetric activity assay service provides a simple and convenient method to determine the caspase activity of the recognition sequence DEVD.
Fluorometric Determination of Caspase-3 Activity
To assess caspase 3 activity, we use a fluorescent caspase-3 detection dye that specifically binds to the active caspase-3 enzyme.
Ace Therapeutics's in vitro caspase-3 activity assay provides customers with a powerful tool to analyze the exact role of caspase-3 in stroke and evaluate potential stroke drugs. If you are interested in our services, please do not hesitate to contact us!
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.